Cormorant Asset Management, LP Centessa Pharmaceuticals PLC Transaction History
Cormorant Asset Management, LP
- $1.74 Billion
- Q1 2024
A detailed history of Cormorant Asset Management, LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Cormorant Asset Management, LP holds 561,600 shares of CNTA stock, worth $5.07 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
561,600
Previous 561,600
-0.0%
Holding current value
$5.07 Million
Previous $4.47 Million
41.97%
% of portfolio
0.37%
Previous 0.27%
Shares
6 transactions
Others Institutions Holding CNTA
# of Institutions
73Shares Held
84.5MCall Options Held
17.7KPut Options Held
5K-
Medicxi Ventures Management (Jersey) LTD20MShares$180 Million59.15% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$90 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$87.4 Million2.56% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.62MShares$50.7 Million1.81% of portfolio
-
Vida Ventures Advisors, LLC3.93MShares$35.5 Million65.7% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $852M
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...